December 20, 2023
Daiichi Sankyo said on December 18 that it has commenced two new PIII studies for its TROP2-directed antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) both for the treatment of breast cancer. The two programs, TROPION-Breast04 and TROPION-Breast05, will look at...read more